Is ESPR or EWTX more undervalued in 2026?

CirclFi compares Esperion Therapeutics, Inc. (ESPR) and Edgewise Therapeutics, Inc. (EWTX) using 13 institutional-grade valuation models. ESPR has a Quality of Company score of 5.2/10 while EWTX scores 4.1/10.

Which is a better buy — ESPR or EWTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ESPR and EWTX valuations compare?

ESPR at $3.13 and EWTX at $34.16 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ESPR vs EWTX Valuation Comparison 2026 — Intrinsic Value Analysis

ESPR

Pharmaceutical Preparations

Esperion Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$3.13

Last close

Models

8/13

Active

EWTX

Pharmaceutical Preparations

Edgewise Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$34.16

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	ESPR Fair Value	ESPR Upside	EWTX Fair Value	EWTX Upside
Bayesian DCF	Intrinsic	$1.10	-65.0%	$10.07	-70.5%
Earnings Power Value	Intrinsic	—	—	$13.97	-55.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$6.15	+96.5%	$49.80	+51.5%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESPR vs EWTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESPR vs EWTX — Which Stock Is More Undervalued?

ESPR scores higher with a 5.2/10 quality rating vs EWTX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Esperion Therapeutics, Inc. (ESPR) and Edgewise Therapeutics, Inc. (EWTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESPR currently trades at $3.13 with a QOC of 5.2/10, while EWTX trades at $34.16 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).